Menstrual blood as a diagnostic tool

Menstrual blood contains endometrial cells, immune cells, stem cells, and hundreds of proteins that reflect reproductive health. Researchers at the Feinstein Institutes (the ROSE study) have shown it can detect endometriosis biomarkers non-invasively, and pilot work shows potential for ovarian cancer screening with 93% accuracy. Yet there are no standardized collection methods, no large-scale validation studies, and almost no clinical adoption.

Menstrual blood stem cells have barely been explored

Menstrual blood-derived mesenchymal stem cells (MenSCs) are non-invasive to collect, ethically uncontroversial, highly proliferative, and do not form tumors. Early trials show promise for multiple sclerosis, type 1 diabetes, Asherman's syndrome, ovarian insufficiency, and spinal cord injury. Despite these advantages over bone marrow-derived stem cells, the field is dramatically behind in funding and clinical development.

No dedicated research found

Endometrial scarless regeneration could transform medicine

The endometrium regenerates up to 400 times over a lifetime without scarring. No other human tissue does this. Understanding the molecular mechanisms behind this process could yield therapies to reduce scarring in cardiac tissue, liver disease, and burn injuries. Despite the enormous potential, the underlying mechanisms remain poorly understood.

No dedicated research found

Drug metabolism varies up to 30% across the menstrual cycle

Estrogen-containing oral contraceptives increase lamotrigine (epilepsy drug) clearance by 50-60%. Caffeine and theophylline metabolism shifts measurably between follicular and luteal phases. Yet clinical trials overwhelmingly do not control for cycle phase, and dosing guidelines make no adjustments for cycling women. The FDA did not require inclusion of women in clinical trials until 1993.

No dedicated research found

The immune system fluctuates across the cycle, but we do not know how

Estrogen and progesterone fluctuations affect immune cell numbers and inflammatory profiles throughout the cycle. A 2024 research review noted that "surprisingly little is known" about these fluctuations. Understanding cycle-dependent immune variation could explain why women have higher autoimmune disease rates and different vaccine responses, but most studies use phone apps rather than hormone-verified methods to track cycle phase.

No dedicated research found

Only 33 neuroimaging studies of hormonal contraceptives have ever been conducted

As of a 2020 systematic review, only 33 total neuroimaging studies had examined how hormonal contraceptives affect the brain. Petersen and Pletzer called this "staggeringly low" given that approximately 150 million women worldwide use them. Nearly all studies examined only oral contraceptives; IUDs, implants, and injectables are virtually unstudied for brain effects.

Adolescent brain development: essentially one study exists

Of all neuroimaging studies of hormonal contraceptives, only one studied an adolescent sample. This is despite the fact that millions of adolescents use hormonal contraception during critical prefrontal cortex maturation. A 2024 study found interaction effects between age of onset and duration of use on hippocampal and prefrontal gray matter volume, but the evidence base remains almost nonexistent.

No dedicated research found

Zero studies on genetic predictors of side effects

No studies have systematically evaluated whether genetic factors can predict hormonal contraceptive side effects. There is considerable interindividual variability in steroid metabolism, meaning the same dose may cause serious side effects in one woman while being well-tolerated by another. This is a massive gap given the push toward precision medicine in every other area of pharmacology.

No dedicated research found

Post-discontinuation effects are dismissed rather than studied

Existing research on stopping hormonal contraceptives focuses narrowly on fertility return and menstruation, ignoring broader health impacts. A 2025 paper in Frontiers documented "a dismissive attitude towards the post-discontinuation experiences of former pill users." LH pulse amplitude and frequency typically take 3-4 months to normalize, and reductions in zinc, magnesium, B6, B12, folate, and selenium have been documented in long-term users.

Chronic inflammation: CRP elevated 3-4x with no explanation for long-term consequences

Oral contraceptive users consistently show C-reactive protein levels elevated 3-4 fold. More than 50% of apparently healthy women on the pill have CRP levels classified as "high-risk" for cardiovascular events. Whether this reflects true systemic inflammation or an isolated liver response, and what the downstream consequences are over decades, is not well studied.

No dedicated research found

Male contraception: no new approved method in over a century

Only 25% of current contraceptive users are male. Promising candidates exist: NES/T gel (86% suppression in Phase 2b), YCT-529 (non-hormonal, Phase 1 complete), and ADAM hydrogel (injectable, 100% success in North American trial). Yet no new male contraceptive method has been approved since the condom. The burden of contraception, and its side effects, falls disproportionately on women.

Long-term neurodegenerative disease risk is essentially unknown

A 2023 scoping review found only 11 studies examining hormonal contraception and risk of cognitive impairment or Alzheimer's disease. Results were mixed, and all relied on retrospective data from post-menopausal women, completely missing the decades when women actually use contraceptives. Given that millions of women take these drugs for 10-20+ years, the absence of prospective data is remarkable.

No dedicated research found

Non-invasive diagnostics are emerging but still unvalidated at scale

Laparoscopic surgery remains the gold standard, contributing to a 6.8-year average diagnostic delay globally. New approaches are in development: Kephera Diagnostics' EndomTest (blood biomarkers), Ziwig's saliva-based miRNA test (sold in 30 countries, not yet US-approved), and NextGen Jane's menstrual blood RNA test. But none have been validated in large, diverse populations.

Research receives $2 per affected person from the NIH

NIH allocated approximately $16 million to endometriosis research in 2022, roughly $2 per affected individual. The same year, diabetes research received $1.1 billion (40x more) and HIV/AIDS received $3.1 billion for 1.2 million patients. For every year of healthy life endometriosis steals, NIH invests 22x less than for Crohn's disease.

No dedicated research found

Autoimmune connection: 2x the odds, no explanation

A large UK Biobank study found women with endometriosis have approximately twice the odds of being diagnosed with at least one autoimmune condition, including rheumatoid arthritis, Hashimoto's, lupus, and multiple sclerosis. University of Oxford research has identified shared genetic pathways, but the mechanism linking these conditions is not understood, and co-management strategies do not exist.

The root cause is still unknown after decades of research

The retrograde menstruation theory does not explain all cases. Genetic, epigenetic, immune, and environmental factors are all implicated, but no unified model exists. The disease presents so variably that clinical trial design is extremely difficult. As researcher Linda Griffith (MIT) has noted, "no treatment has worked for all patients" precisely because of this heterogeneity.

Gut microbiome-endometriosis axis is a new frontier

A 2025 systematic review and meta-analysis found gut microbiome dysbiosis drives chronic inflammation, immune dysfunction, and altered bacterial taxa in endometriosis patients. The gut microbiota influences estrogen metabolism, which directly affects disease progression. Probiotics and dietary modifications are promising but entirely unstudied as therapeutic interventions.

PFAS "forever chemicals" may reduce fertility by up to 40%

NIEHS-funded research found PFAS exposure may reduce fertility in women by up to 40%. A meta-analysis found 5-10% reduction in fecundability per quartile increase in PFAS exposure, and a 2024 study found PFAS mixtures damage high-quality embryos in IVF patients. Sperm concentration has declined 52% in Western men since 1973 (Shanna Swan, Mount Sinai), with endocrine disruptors implicated. Well-designed longitudinal cohort studies are still needed.

Only 6% of women who freeze their eggs return to use them

A 2025 study found just 6% of women who froze their eggs returned to use them within 7 years, while elective egg freezing cycles nearly quadrupled from 2014 to 2021. When used, success rates are comparable to fresh IVF. The disconnect between aggressive marketing and the 6% utilization rate is itself an under-studied phenomenon. Long-term outcome data for very long storage periods (10+ years) is also limited.

IVF "add-ons" have no proven efficacy, and most patients are not told

The WHO issued its first global infertility guideline in 2025, acknowledging major evidence gaps in treatment. Of 14 IVF add-on treatments assessed by the UK's HFEA, none received a "proven safe and effective" rating. A 2025 patient survey found most patients are not informed of this. There is no US equivalent to this traffic-light rating system.

No dedicated research found

Male factor infertility receives a fraction of research funding

Male factors contribute to roughly half of all infertility cases, yet male reproductive health research receives dramatically less funding. ESHRE's 2024 priority-setting exercise identified male infertility as a significant knowledge gap, noting that modifiable risk factors and sperm testing for predicting outcomes are both inadequately studied. The burden of treatment falls disproportionately on women.

No dedicated research found

Only 44% of cancer patients are counseled about fertility preservation

A 2025 ASCO guideline update now recommends fertility preservation in survivorship care after cancer treatment, not just at diagnosis. Yet only 44% of patients are counseled about infertility risks from chemotherapy. Ovarian tissue cryopreservation remains the only option for prepubertal girls but is still experimental, with zero live births reported from tissue frozen before puberty.

No dedicated research found

Four data-driven subtypes identified, but treatment is still one-size-fits-all

A 2025 Nature Medicine study of 11,908 women identified four reproducible PCOS subtypes with distinct risk profiles: hyperandrogenic (highest dyslipidemia), obesity-driven (highest diabetes risk but highest remission rate), high-SHBG (most favorable outcomes), and high-LH/AMH (prone to ovarian hyperstimulation). Subtype-specific treatment could dramatically improve precision, but current clinical practice does not differentiate.

No dedicated research found

NIH averaged $32 million/year on PCOS, despite affecting 8-13% of women

PCOS was not even included in NIH's Research, Condition, and Disease Categorization until 2022. Average annual funding from 2016-2022 was $31.84 million, compared to $262 million for rheumatoid arthritis and $420 million for lupus. 70% of women with PCOS remain undiagnosed. The 2023 International PCOS Guideline found some recommendations rely on expert consensus rather than high-quality trial evidence due to persistent research gaps.

Depression rates of 47% and anxiety of 40% are routinely overlooked in care

Depression prevalence in PCOS patients is approximately 47.7% and anxiety 39.9%, rates 3-8x higher than in controls. Yet mental health is routinely overlooked in clinical PCOS management. No known studies focus on the biological mechanisms underlying the elevated anxiety rates. Almost no research exists on PCOS mental health in low- and middle-income countries, where cultural stigma compounds the problem.

No dedicated research found

Lean PCOS is systematically under-studied and misdiagnosed

Women with PCOS who have a normal BMI are frequently dismissed because the condition is stereotypically associated with obesity. Lean PCOS may have distinct metabolic profiles and treatment needs, and the 2023 guideline roadmap (co-designed with 1,278 patients) specifically identified optimizing diagnosis across diverse populations and life stages as a top priority.

The gut microbiome-PCOS connection is real but unexplored clinically

Systematic reviews consistently show PCOS patients have gut dysbiosis: reduced microbial diversity, altered Firmicutes/Bacteroidetes ratio, and fewer butyrate-producing bacteria. Dysbiosis worsens insulin resistance and androgen excess via the "gut-ovary axis." Prebiotics, fecal microbiota transplantation, and dietary optimization are all promising, but clinical evidence in humans remains limited to observational studies.

72% lifetime suicidal ideation, yet no standard screening exists

An IAPMD global survey of prospectively diagnosed PMDD patients found 72% lifetime suicidal ideation, 34% lifetime suicide attempt, and 51% non-suicidal self-injury. This link appears independent of depression or PTSD. Despite these numbers, there is still no recommended standard screening protocol for suicidality in PMDD patients, and emergency protocols do not account for cyclical psychiatric symptoms.

Average diagnosis takes 12-20 years

PMDD was only added to the DSM-5 in 2013. The gold-standard diagnosis requires daily symptom ratings across two full menstrual cycles, which is impractical in most clinical settings. Many women receive diagnoses of major depression, bipolar disorder, or generalized anxiety before PMDD is identified. Lack of recognition leads to underestimated prevalence, which leads to reduced research funding, perpetuating the cycle.

PME (premenstrual exacerbation) is not formally recognized as a diagnosis

Over 50% of women with mood disorders experience premenstrual exacerbation, where an underlying condition worsens in the luteal phase but never fully resolves after menstruation. PME requires fundamentally different treatment from PMDD, but is not a formal clinical diagnosis. There is no standardized protocol for distinguishing the two, meaning many patients receive inappropriate treatments.

Emerging neurosteroid treatments are promising but not yet available for PMDD

Zuranolone (approved for postpartum depression in 2023) targets the same GABA-A receptor pathway implicated in PMDD, but has not yet entered PMDD-specific trials. Sepranolone, designed specifically for PMDD, showed significance only in post-hoc analysis in Phase II. Beyond SSRIs and hormonal suppression, women who do not respond to first-line treatments have very few evidence-based options.

The neurosteroid mechanism is compelling but not fully proven

The leading theory suggests abnormal sensitivity to allopregnanolone at GABA-A receptors, with NIH researchers finding the ESC/E(Z) epigenetic complex altered in over 50% of women with PMDD. A 2025 study linked decreased GABA-A receptor delta subunit expression to higher amygdala activation in the luteal phase. But the mechanism is not fully validated, and predicting who will develop PMDD is still not possible.

Cycle-based nutrition research is in its infancy

A 2023 systematic review described the evidence for menstrual-cycle-based dietary interventions as being in the "infancy of robust studies." Results are conflicting, methodological inconsistencies are widespread, and a meta-analysis was not even possible due to the small number of studies. Whether nutrient absorption varies by cycle phase, and how hormonal contraceptives change this, remains unaddressed.

No dedicated research found

50% of women in high-income countries are deficient in iron, zinc, or folate

A 2024 JAMA Network Open study found approximately 50% of non-pregnant women ages 15-49 in high-income countries are deficient in at least one of iron, zinc, and folate. Globally the figure is 69%, affecting 1.2 billion women. Despite this scale, dosing guidelines for most micronutrients were established using primarily male study populations, and recommendations across the reproductive lifespan are inconsistent.

No dedicated research found

The estrobolome links gut bacteria to hormone-driven disease

The "estrobolome" refers to gut bacterial genes that metabolize estrogens via beta-glucuronidase enzymes, influencing circulating estrogen levels. Dysbiosis alters estrogen recirculation and is linked to breast cancer, endometriosis, and PCOS. But only a few mechanistic studies exist, interventional clinical trials are absent, and the field needs advanced sequencing and metabolomics to move beyond associational findings.

Supplement-drug interactions are poorly mapped in women

St. John's Wort speeds up CYP enzymes, lowering birth control hormone levels. Calcium blocks thyroid medication absorption. But most contraceptive drugs were developed before modern bioanalytical techniques, and researchers often extrapolate from other drug interaction studies with only a small number of cases. Whether many common supplement-medication combinations are synergistic, redundant, or harmful is mostly unknown.

No dedicated research found

Hormonal fluctuations and neurodivergent symptom expression

Women with ADHD have significantly increased risk of PMDD, and widespread patient reports describe cyclical worsening of ADHD and autism symptoms. Yet the relationship between cycling hormones and neurodivergent conditions in women is barely studied. No RCT evidence exists for hormone-aware treatment approaches.

Fewer than 1% of preclinical aging studies consider menopause

Harvard researchers found that fewer than 1% of published preclinical aging studies account for menopause, despite the fact that women live roughly a third of their lives post-menopausal and over 75% of age-related diseases are likely influenced by it. Reliable animal models of menopause are lacking, creating a foundational gap in understanding how menopause contributes to disease.

No dedicated research found

Two-thirds of Alzheimer's patients are women, and menopause may be why

Perimenopause represents a "critical window of emerging vulnerability" to Alzheimer's-related brain changes. In mouse models, early ovarian failure enhances amyloid accumulation in the hippocampus. But a 2025 Lancet systematic review found the available evidence does not support HRT solely for dementia risk reduction, and found no eligible studies specifically addressing women with early menopause or premature ovarian insufficiency.

No dedicated research found

Fewer than 20% of OB/GYN residents receive adequate menopause training

Only 31% of primary care providers correctly identified the expected duration of menopausal symptoms. Medical education devotes minimal time to menopause management. Fewer than 15% of menopausal women receive effective treatment. The Lancet's 2024 Menopause Priority Setting Partnership (2,125 respondents, 42 countries) identified clinician preparedness as a top-10 priority.

Genitourinary syndrome of menopause: no data beyond one year

Vulvovaginal atrophy and genitourinary symptoms affect the majority of postmenopausal women, yet 2024-2025 guideline reviews found almost no efficacy or safety data beyond one year of treatment. Studies underrepresent older women and racially diverse populations. Many women are never asked about these symptoms, and many clinicians do not raise the topic.

No dedicated research found

Early menopause has no prevention strategy

Premature ovarian insufficiency (before age 40) increases cardiovascular risk, osteoporosis, and psychological distress. In most cases the cause is unknown. A 2025 ASRM guideline found no validated biomarkers for personalizing therapy, stem cell approaches are in early stages, and clinical trials consistently underrepresent ethnic minorities and women with comorbidities.

No dedicated research found

Why thyroid disease is 5-8x more common in women: three competing mechanisms

The X chromosome, estrogen signaling, and epigenetic modifications are all implicated, but which matters most is unclear. Skewed X-chromosome inactivation is found in 34% of female autoimmune thyroid disease patients vs. 11% of controls. Immune-relevant genes (TLR7, FOXP3, CD40L) escape X-inactivation. Estrogen promotes Th1 lymphocyte responses that drive Hashimoto's. These mechanisms interact in ways that are still not characterized.

Treating subclinical hypothyroidism in pregnancy: two large RCTs found no benefit

Two major randomized trials (UK CATS, US NIH) found levothyroxine started at 13-17 weeks gestation did not improve obstetric or neurodevelopmental outcomes. A smaller trial showed lower preterm birth with first-trimester treatment. Whether, when, and at what TSH threshold to treat remains genuinely unresolved. Trimester-specific reference ranges should be established locally but rarely are.

Thyroid-reproductive hormone interactions are understood only in broad strokes

Thyroid dysfunction disrupts menstrual cycles, fertility, and pregnancy outcomes. Anti-TPO antibodies may accelerate ovarian aging. But how thyroid hormones interact with estrogen, progesterone, and FSH/LH at the cellular level is incompletely characterized. Evidence is insufficient to say whether prior pregnancy affects subsequent thyroid function.

No dedicated research found

Hashimoto's is the most common autoimmune disease, yet poorly understood

Hashimoto's thyroiditis is 10-15 times more frequent in women than men and is the most prevalent autoimmune disorder among women of reproductive age. The gender gap becomes especially pronounced at puberty, pregnancy, and menopause. Despite this, the compounded effects of biological sex, hormones, and social determinants on Hashimoto's outcomes have not been studied with inclusive designs.

The timing hypothesis has never been tested in a definitive RCT

Cumulated evidence supports a "window of opportunity" for cardiovascular benefit when HRT is initiated before age 60. The ELITE trial showed estradiol started within 6 years of menopause slows arterial disease. But no large-scale randomized controlled trial has been specifically designed to test the timing hypothesis with hard clinical endpoints like heart attack and stroke.

Micronized progesterone vs. synthetic progestins: no head-to-head RCT for safety

Systematic reviews show estrogen combined with micronized progesterone is not associated with increased breast cancer risk for up to 5 years, while synthetic progestins are. The PROBES trial (protocol published 2024) is the first to directly compare the two, but is limited to one year and uses surrogate markers. No trial has directly compared them for cancer or cardiovascular outcomes.

No FDA-approved testosterone formulation exists for women

Thirty-six randomized trials with 8,480 participants demonstrate short-term efficacy and safety of testosterone for postmenopausal low sexual desire, but only up to 24 months. Off-label use for energy, cognition, and mood is growing, yet evidence supports only the sexual desire indication. Cardiovascular, metabolic, and cancer outcomes with long-term use are unknown. No data support use in premenopausal women.

Compounded "bioidentical" hormones are marketed without evidence

The FDA states it does not have evidence that compounded bioidentical hormones are safe and effective, or safer than FDA-approved formulations. The National Academies recommend restricting their use to allergy cases or unavailable dosage forms. No high-quality placebo-controlled RCTs with long-term follow-up have compared compounded products with FDA-approved hormone therapy. Yet they are widely marketed as safer or more natural alternatives.